Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9072903 | 0.92 | NPC1 (0.43) | GCKUSP30 | |
| SCHEMBL9072799 | 0.77 | CTSS (0.52) | GCKUSP30CTSS | |
| SCHEMBL9072800 | 0.76 | GCK (0.42) | GCKUSP30CTSS | |
| SCHEMBL2669248 | 0.75 | GCK (0.41) | GCKUSP30PSMB10PSMB2CTSS | |
| SCHEMBL2518491 | 0.74 | GCK (0.51) | GCK | |
| SCHEMBL2669273 | 0.74 | AAK1 (0.47) | GCK | |
| SCHEMBL2645999 | 0.72 | GCK (0.59) | GCKKCNH2 | |
| SCHEMBL2647945 | 0.70 | KCNH2 (0.44) | GCKKCNH2 | |
| SCHEMBL9072905 | 0.70 | CTSS (0.52) | GCKUSP30CTSS | |
| SCHEMBL2515764 | 0.69 | GCK (0.54) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034822-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885USP30 4005/4885PSMB10 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.